Interleukin 24 gene therapy - MultiVir

Drug Profile

Interleukin 24 gene therapy - MultiVir

Alternative Names: Ad-IL 24 - MultiVir; Ad-IL24; Adenoviral interleukin 24 - MultiVir; IL24 gene therapy - MultiVir

Latest Information Update: 31 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MultiVir
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Malignant melanoma
  • No development reported Head and neck cancer

Most Recent Events

  • 18 May 2017 Results from a preclinical trial in Malignant melanoma released by MultiVir
  • 15 Apr 2016 Phase-I clinical trials in Malignant melanoma (Combination therapy) in USA (unspecified route)
  • 14 Feb 2014 Phase-I clinical trials in Head and neck cancer (combination therapy, recurrent) in USA (unspecified route) before February 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top